There has been a randomized clinical trial that proved that 6 mos. of adjuvant ADT with SRT is better than none. An earlier clinical trial (RTOG 9601) showed a benefit to years of bicalutamide vs none. These, and other retrospective studies are discussed here:
/pcnrv.blogspot.com/2016/08/combining-androgen-deprivation-therapy.htmlHowever, in a retrospective study, researchers identified a group of patients in whom adjuvant ADT could safely be avoided. They found that it could be avoided in men with the following characteristics:
• Only those with a 10-year probability of distant metastases (based on PSA at the time of SRT) greater than 1 in 3 benefited from the addition of ADT
• The benefit grew exponentially with increasing risk
• Adjuvant ADT only benefited those with higher PSA (≥0.4 ng/ml), Gleason score 8-10, stage T3b/4.
• Higher SRT dose and whole pelvic SRT improved outcomes independently of whether adjuvant ADT was used.
/pcnrv.blogspot.com/2018/01/when-can-adt-be-safely-avoided-with.htmlThis begs the question of whether you need SRT at all. Based on your Decipher score, favorable disease characteristics, and very slow increase in PSA, I think you should hold off until you have a consistent pattern of increasing PSA. It is likely that some small amount of Gleason 6 was left behind, and most Gleason 6 never needs treatment:
/pcnrv.blogspot.com/2017/11/myth-gleason-6-never-progresses.html